Clinical Trial Update: A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B [Phase 3]

View source ↗

Summary

A Phase 3 extension study evaluated the safety and efficacy of rIX-FP in patients with Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rIX-FP (recombinant coagulation factor IX albumin fusion protein)

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2022-07-14